# Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

> **NCT05204862** · PHASE1,PHASE2 · RECRUITING · sponsor: **TiumBio Co., Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** TU2218
- **DRUG:** Anti-PD-1 antibody

## Key facts

- **NCT ID:** NCT05204862
- **Lead sponsor:** TiumBio Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-02
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2023-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05204862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05204862, "Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05204862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*